• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Interferon therapy in myelomatosis.

作者信息

Mellstedt H, Ahre A, Björkholm M, Holm G, Johansson B, Strander H

出版信息

Lancet. 1979 Feb 3;1(8110):245-7. doi: 10.1016/s0140-6736(79)90770-0.

DOI:10.1016/s0140-6736(79)90770-0
PMID:84901
Abstract

Four patients with myelomatosis (one IgG-chi-type, two IgA-chi, and one Bence Jones-x) were given human leucocyte interferon as the only treatment for from 3 to 19 months. Remission was complete in two patients and partial in the other two. Normal bone-marrow haematopoiesis was slightly inhibited. The disease has not so far progressed in any of the patients.

摘要

相似文献

1
Interferon therapy in myelomatosis.
Lancet. 1979 Feb 3;1(8110):245-7. doi: 10.1016/s0140-6736(79)90770-0.
2
[Meningeal myelomatosis as an exclusive form of recurrence in a case of IgA-lambda myeloma in complete systemic remission].
Med Clin (Barc). 1991 Oct 19;97(13):503-5.
3
Benign Bence Jones gammopathy.良性本-周蛋白丙种球蛋白病
Acta Haematol. 1980;63(5):241-6. doi: 10.1159/000207409.
4
Immunochemical studies in multiple myeloma.多发性骨髓瘤的免疫化学研究。
Indian J Cancer. 1997 Dec;34(4):151-8.
5
Serum test for assessment of patients with Bence Jones myeloma.用于评估本-周蛋白骨髓瘤患者的血清检测
Lancet. 2003 Feb 8;361(9356):489-91. doi: 10.1016/S0140-6736(03)12457-9.
6
Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria.接受序贯治疗的本-周氏蛋白、IgG和IgA骨髓瘤新患者的比较:需要将这些免疫亚型视为具有特定预后标准的独立疾病实体。
Bone Marrow Transplant. 2001 Jul;28(1):29-37. doi: 10.1038/sj.bmt.1703093.
7
Monitoring myelomatosis.监测骨髓瘤
Arch Intern Med. 1975 Jan;135(1):125-30.
8
Correlation of abnormal immunoglobulin with clinical features of myeloma.异常免疫球蛋白与骨髓瘤临床特征的相关性
Arch Intern Med. 1975 Jan;135(1):46-52.
9
Prognostic factors in myelomatosis.骨髓瘤的预后因素。
Br Med J. 1971 May 8;2(5757):327-8. doi: 10.1136/bmj.2.5757.327-b.
10
Intracytoplasmic and surface-bound immunoglobulins in "nonsecretory" and Bence-Jones myeloma.“非分泌型”和本-周蛋白骨髓瘤中的胞浆内及表面结合免疫球蛋白
Clin Exp Immunol. 1976 Sep;25(3):428-36.

引用本文的文献

1
Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses.分子特征将 VQ 骨髓瘤细胞分为具有不同风险特征和药物反应的两个簇。
Oncogene. 2023 May;42(21):1751-1762. doi: 10.1038/s41388-023-02684-9. Epub 2023 Apr 8.
2
Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.重组干扰素-β在真性红细胞增多症及相关肿瘤治疗中的应用:理论依据与前景
Cancers (Basel). 2022 Nov 9;14(22):5495. doi: 10.3390/cancers14225495.
3
Facts and Hopes in Multiple Myeloma Immunotherapy.
多发性骨髓瘤免疫治疗的现状与展望。
Clin Cancer Res. 2021 Aug 15;27(16):4468-4477. doi: 10.1158/1078-0432.CCR-20-3600. Epub 2021 Mar 26.
4
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?干扰素-α在治疗真性红细胞增多症和相关骨髓增殖性肿瘤中的作用观点:微小残留病和治愈?
Semin Immunopathol. 2019 Jan;41(1):5-19. doi: 10.1007/s00281-018-0700-2. Epub 2018 Sep 10.
5
Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.一种效力匹配的双细胞因子-抗体融合蛋白增强 PD-L1 阻断作用,可导致 BALB/c 来源肿瘤的消除,但不能导致其他小鼠品系肿瘤的消除。
Cancer Immunol Immunother. 2018 Sep;67(9):1381-1391. doi: 10.1007/s00262-018-2194-0. Epub 2018 Jul 4.
6
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity.用CD38抗体将减毒干扰素-α靶向骨髓瘤细胞可诱导有效的肿瘤消退并降低脱靶活性。
PLoS One. 2016 Sep 9;11(9):e0162472. doi: 10.1371/journal.pone.0162472. eCollection 2016.
7
Type I interferons in anticancer immunity.I 型干扰素在癌症免疫中的作用。
Nat Rev Immunol. 2015 Jul;15(7):405-14. doi: 10.1038/nri3845. Epub 2015 Jun 1.
8
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.一种新型 TLR-9 激动剂 C792 抑制浆细胞样树突状细胞诱导的骨髓瘤细胞生长并增强硼替佐米的细胞毒性。
Leukemia. 2014 Aug;28(8):1716-24. doi: 10.1038/leu.2014.46. Epub 2014 Jan 30.
9
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma.沙利度胺维持治疗可提高老年骨髓瘤患者的无进展生存期,但不能提高总生存期。
Haematologica. 2010 Sep;95(9):1548-54. doi: 10.3324/haematol.2009.020586. Epub 2010 Apr 23.
10
Cancer immunotherapy: potential involvement of mediators.癌症免疫疗法:潜在的介质参与。
Mediators Inflamm. 1997;6(3):163-73. doi: 10.1080/09629359791659.